145 related articles for article (PubMed ID: 29979193)
21. miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
Husby S; Ralfkiaer U; Garde C; Zandi R; Ek S; Kolstad A; Jerkeman M; Laurell A; Räty R; Pedersen LB; Pedersen A; Ehinger M; Sundström C; Karjalainen-Lindsberg ML; Delabie J; Clasen-Linde E; Brown P; Cowland JB; Workman CT; Geisler CH; Grønbæk K
Blood; 2015 Apr; 125(17):2669-77. PubMed ID: 25736311
[TBL] [Abstract][Full Text] [Related]
22. CCL21/CCR7 up-regulate vascular endothelial growth factor-D expression via ERK pathway in human non-small cell lung cancer cells.
Sun L; Zhang Q; Li Y; Tang N; Qiu X
Int J Clin Exp Pathol; 2015; 8(12):15729-38. PubMed ID: 26884842
[TBL] [Abstract][Full Text] [Related]
23. CCL21/CCR7 interaction promotes cellular migration and invasion via modulation of the MEK/ERK1/2 signaling pathway and correlates with lymphatic metastatic spread and poor prognosis in urinary bladder cancer.
Xiong Y; Huang F; Li X; Chen Z; Feng D; Jiang H; Chen W; Zhang X
Int J Oncol; 2017 Jul; 51(1):75-90. PubMed ID: 28534984
[TBL] [Abstract][Full Text] [Related]
24. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma.
Zhao JJ; Lin J; Lwin T; Yang H; Guo J; Kong W; Dessureault S; Moscinski LC; Rezania D; Dalton WS; Sotomayor E; Tao J; Cheng JQ
Blood; 2010 Apr; 115(13):2630-9. PubMed ID: 20086245
[TBL] [Abstract][Full Text] [Related]
25. Contribution of homeostatic chemokines CCL19 and CCL21 and their receptor CCR7 to coronary artery disease.
Cai W; Tao J; Zhang X; Tian X; Liu T; Feng X; Bai J; Yan C; Han Y
Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):1933-41. PubMed ID: 24990231
[TBL] [Abstract][Full Text] [Related]
26. MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11.
Wu B; Li J; Wang H; Wu Q; Liu H
Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2197-2208. PubMed ID: 32040593
[TBL] [Abstract][Full Text] [Related]
27. miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11.
Zhou K; Feng X; Wang Y; Liu Y; Tian L; Zuo W; Yi S; Wei X; Song Y; Qiu L
Exp Hematol; 2018 Feb; 58():27-34.e1. PubMed ID: 29158064
[TBL] [Abstract][Full Text] [Related]
28. CCR7-CCL19/CCL21 Axis is Essential for Effective Arteriogenesis in a Murine Model of Hindlimb Ischemia.
Nossent AY; Bastiaansen AJ; Peters EA; de Vries MR; Aref Z; Welten SM; de Jager SC; van der Pouw Kraan TC; Quax PH
J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28275068
[TBL] [Abstract][Full Text] [Related]
29. Slug signaling is up-regulated by CCL21/CCR7 [corrected] to induce EMT in human chondrosarcoma.
Li G; Yang Y; Xu S; Ma L; He M; Zhang Z
Med Oncol; 2015 Feb; 32(2):478. PubMed ID: 25556164
[TBL] [Abstract][Full Text] [Related]
30. Iodine regulates G2/M progression induced by CCL21/CCR7 interaction in primary cultures of papillary thyroid cancer cells with RET/PTC expression.
Zhang YY; Liu ZB; Ye XG; Ren WM
Mol Med Rep; 2016 Oct; 14(4):3941-6. PubMed ID: 27574129
[TBL] [Abstract][Full Text] [Related]
31. The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.
Rao E; Jiang C; Ji M; Huang X; Iqbal J; Lenz G; Wright G; Staudt LM; Zhao Y; McKeithan TW; Chan WC; Fu K
Leukemia; 2012 May; 26(5):1064-72. PubMed ID: 22116552
[TBL] [Abstract][Full Text] [Related]
32. Ets-1 enhances tumor migration through regulation of CCR7 expression.
Fang LW; Kao YH; Chuang YT; Huang HL; Tai TS
BMB Rep; 2019 Sep; 52(9):548-553. PubMed ID: 31072446
[TBL] [Abstract][Full Text] [Related]
33. MiR-let-7a/f-CCR7 signaling is involved in the anti-metastatic effects of an herbal formula comprising Sophorae Flos and Lonicerae Japonicae Flos in melanoma.
Liu YX; Bai JX; Li T; Fu XQ; Chen YJ; Zhu PL; Chou JY; Yin CL; Li JK; Wang YP; Wu JY; Yu ZL
Phytomedicine; 2019 Nov; 64():153084. PubMed ID: 31514083
[TBL] [Abstract][Full Text] [Related]
34. Mantle cell lymphoma: transcriptional regulation by microRNAs.
Di Lisio L; Gómez-López G; Sánchez-Beato M; Gómez-Abad C; Rodríguez ME; Villuendas R; Ferreira BI; Carro A; Rico D; Mollejo M; Martínez MA; Menárguez J; Díaz-Alderete A; Gil J; Cigudosa JC; Pisano DG; Piris MA; Martínez N
Leukemia; 2010 Jul; 24(7):1335-42. PubMed ID: 20485376
[TBL] [Abstract][Full Text] [Related]
35. MiR-199a/b-3p inhibits gastric cancer cell proliferation via down-regulating PAK4/MEK/ERK signaling pathway.
Zeng B; Shi W; Tan G
BMC Cancer; 2018 Jan; 18(1):34. PubMed ID: 29304764
[TBL] [Abstract][Full Text] [Related]
36. Identification of miR-15b as a transformation-related factor in mantle cell lymphoma.
Arakawa F; Kimura Y; Yoshida N; Miyoshi H; Doi A; Yasuda K; Nakajima K; Kiyasu J; Niino D; Sugita Y; Tashiro K; Kuhara S; Seto M; Ohshima K
Int J Oncol; 2016 Feb; 48(2):485-92. PubMed ID: 26676972
[TBL] [Abstract][Full Text] [Related]
37. The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C.
Bonacchi A; Petrai I; Defranco RM; Lazzeri E; Annunziato F; Efsen E; Cosmi L; Romagnani P; Milani S; Failli P; Batignani G; Liotta F; Laffi G; Pinzani M; Gentilini P; Marra F
Gastroenterology; 2003 Oct; 125(4):1060-76. PubMed ID: 14517790
[TBL] [Abstract][Full Text] [Related]
38. NLK, a novel target of miR-199a-3p, functions as a tumor suppressor in colorectal cancer.
Han Y; Kuang Y; Xue X; Guo X; Li P; Wang X; Guo X; Yuan B; Zhi Q; Zhao H
Biomed Pharmacother; 2014 Jun; 68(5):497-505. PubMed ID: 24972723
[TBL] [Abstract][Full Text] [Related]
39. Site-Specific Polyplex on CCR7 Down-Regulation and T Cell Elevation for Lymphatic Metastasis Blocking on Breast Cancer.
Deng Y; Tan C; Huang S; Sun H; Li Z; Li J; Zhou Z; Sun M
Adv Healthc Mater; 2022 Nov; 11(22):e2201166. PubMed ID: 36113849
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma.
Goswami RS; Atenafu EG; Xuan Y; Waldron L; Reis PP; Sun T; Datti A; Xu W; Kuruvilla J; Good DJ; Lai R; Church AJ; Lam WS; Baetz T; Lebrun DP; Sehn LH; Farinha P; Jurisica I; Bailey DJ; Gascoyne RD; Crump M; Kamel-Reid S
J Clin Oncol; 2013 Aug; 31(23):2903-11. PubMed ID: 23835716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
